244 related articles for article (PubMed ID: 29342200)
1. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Otegbeye F; Ojo E; Moreton S; Mackowski N; Lee DA; de Lima M; Wald DN
PLoS One; 2018; 13(1):e0191358. PubMed ID: 29342200
[TBL] [Abstract][Full Text] [Related]
2. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
3. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
4. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.
Yvon ES; Burga R; Powell A; Cruz CR; Fernandes R; Barese C; Nguyen T; Abdel-Baki MS; Bollard CM
Cytotherapy; 2017 Mar; 19(3):408-418. PubMed ID: 28109751
[TBL] [Abstract][Full Text] [Related]
5. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
6. Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.
Chaudhry K; Dowlati E; Long MD; Geiger A; Lang H; Gomez EC; Muniraj N; Sanchez CE; Singh PK; Liu S; Bollard CM; Cruz CRY
Cytotherapy; 2022 Aug; 24(8):802-817. PubMed ID: 35589475
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.
Shenouda MM; Gillgrass A; Nham T; Hogg R; Lee AJ; Chew MV; Shafaei M; Aarts C; Lee DA; Hassell J; Bane A; Dhesy-Thind S; Ashkar AA
Breast Cancer Res; 2017 Jul; 19(1):76. PubMed ID: 28668076
[TBL] [Abstract][Full Text] [Related]
8. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
9. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
[TBL] [Abstract][Full Text] [Related]
10.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
11. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
[TBL] [Abstract][Full Text] [Related]
12. Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β.
Brownlie D; Doughty-Shenton D; Yh Soong D; Nixon C; O Carragher N; M Carlin L; Kitamura T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472858
[TBL] [Abstract][Full Text] [Related]
13. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.
Lee JC; Lee KM; Kim DW; Heo DS
J Immunol; 2004 Jun; 172(12):7335-40. PubMed ID: 15187109
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice.
Nishio M; Sugimachi K; Goto H; Wang J; Morikawa T; Miyachi Y; Takano Y; Hikasa H; Itoh T; Suzuki SO; Kurihara H; Aishima S; Leask A; Sasaki T; Nakano T; Nishina H; Nishikawa Y; Sekido Y; Nakao K; Shin-Ya K; Mimori K; Suzuki A
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E71-80. PubMed ID: 26699479
[TBL] [Abstract][Full Text] [Related]
16. The role of transforming growth factor-beta in suppression of hepatic metastasis from colon cancer.
Are C; Simms N; Rajput A; Brattain M
HPB (Oxford); 2010 Sep; 12(7):498-506. PubMed ID: 20815859
[TBL] [Abstract][Full Text] [Related]
17. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.
Wilson EB; El-Jawhari JJ; Neilson AL; Hall GD; Melcher AA; Meade JL; Cook GP
PLoS One; 2011; 6(9):e22842. PubMed ID: 21909397
[TBL] [Abstract][Full Text] [Related]
18. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
19. Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8
Liu B; Zhu X; Kong L; Wang M; Spanoudis C; Chaturvedi P; George V; Jiao JA; You L; Egan JO; Echeverri C; Gallo VL; Xing J; Ravelo K; Prendes C; Antolinez J; Denissova J; Muniz GJ; Jeng EK; Rhode PR; Wong HC
Mol Ther; 2021 Oct; 29(10):2949-2962. PubMed ID: 34091051
[TBL] [Abstract][Full Text] [Related]
20. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
